Global and United States Rapid Diagnostic Testing for Influenza Market Size, Status and Forecast 2021-2027

Rapid influenza diagnostic tests (RIDTs) are immunoassays that can identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens, and display the result in a qualitative way (positive vs. negative). In the United States, a number of RIDTs are commercially available. The reference standards for laboratory confirmation of influenza virus infection in respiratory specimens are reverse transcription-polymerase chain reaction (RT-PCR) or viral culture. RIDTs can yield results in a clinically relevant time frame, i.e., less than approximately 15 minutes. However, RIDTs have limited sensitivity to detect influenza viruses in respiratory specimens compared to RT-PCR or viral culture and negative RIDT test results should be interpreted with caution given the potential for false negative results, especially during peak influenza activity in a community. Some RIDTs use analyzer reader devices to standardize result interpretation.
The classification of Rapid Influenza Diagnostic Test (RIDT) includes Conventional RIDT and Digital RIDTs. The proportion of digital RIDTs in 2018 is about 53.35% of revenue.Rapid Influenza Diagnostic Test (RIDT) is application in hospital, POCT and others. The most of Rapid Influenza Diagnostic Test (RIDT) is used in hospital, and the market share of that is about 63.97% in 2018.North America is the largest consumption place, with a consumption market share nearly 53.65% in 2018. Following North America, Europe is the second largest consumption place with the consumption market share of 26.27% in 2018.

Market competition is intense. BD, Abbot (Alere), Quidel, Roche, Thermo Fisher Scientific, Meridian Bioscience, Analytik Jena, Princeton BioMeditech Corporation, BioMerieux, Sekisui Diagnostics, Response Biomedical, SA Scientific, DiaSorin (Focus Diagnostics) are the leaders of the industry, and have been formed in the monopoly position in the industry.

Market Analysis and Insights: Global Rapid Diagnostic Testing for Influenza Market
The global Rapid Diagnostic Testing for Influenza market size is projected to reach US$ 1963.6 million by 2027, from US$ 1063.6 million in 2020, at a CAGR of 9.0% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Rapid Diagnostic Testing for Influenza market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Rapid Diagnostic Testing for Influenza market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Rapid Diagnostic Testing for Influenza market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Rapid Diagnostic Testing for Influenza market.

Global Rapid Diagnostic Testing for Influenza Scope and Market Size
Rapid Diagnostic Testing for Influenza market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Rapid Diagnostic Testing for Influenza market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Digital RIDTs
Conventional RIDT

Segment by Application
Hospitals
POCT
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
BD
Abbot (Alere)
Quidel
Roche
Thermo Fisher Scientific
Meridian Bioscience
Analytik Jena
Princeton BioMeditech Corporation
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
DiaSorin (Focus Diagnostics)
Wondfo
Beijing Wantai Biological Pharmacy